Ikarian Capital’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.38M Hold
90,183
– – 0.14% 116
2026
Q2
$1.67M Buy
+90,183
New +$1.43M 0.18% 94
2026
Q1
– Sell
-31,106
Closed -$486K – 171
2025
Q4
$565K Sell
31,106
-128,671
-81% -$2.17M 0.04% 136
2025
Q3
$2.03M Buy
159,777
+124,477
+353% +$1.07M 0.21% 98
2025
Q2
$176K Sell
35,300
-164,700
-82% -$769K 0.03% 116
2025
Q1
$1.6M Sell
200,000
-770,259
-79% -$5.84M 0.2% 77
2024
Q4
$7.21M Sell
970,259
-100
-0% -$1.07K 0.98% 27
2024
Q3
$9.22M Buy
970,359
+915,629
+1,673% +$9.44M 1.29% 20
2024
Q2
$682K Buy
54,730
+8,082
+17% +$105K 0.12% 86
2024
Q1
$1.01M Buy
+46,648
New +$251K 0.11% 105
2022
Q2
– Sell
-265
Closed -$554K – 148
2022
Q1
$554K Buy
265
+15
+6% +$37.7K 0.07% 130
2021
Q4
$1.22M Hold
250
– – 0.18% 89
2021
Q3
$1.57M Sell
250
-62
-20% -$503K 0.11% 138
2021
Q2
$2.93M Hold
312
– – 0.24% 100
2021
Q1
$2.71M Buy
312
+242
+346% +$2.29M 0.09% 180
2020
Q4
$536K Hold
70
– – 0.02% 189
2020
Q3
$460K Sell
70
-70
-50% -$526K 0.03% 144
2020
Q2
$1.05M Sell
140
-56
-29% -$407K 0.08% 122
2020
Q1
$1.4M Buy
196
+16
+9% +$169K 0.11% 107
2019
Q4
$2.8M Buy
+180
New +$1.9M 0.45% 54

Other funds holding AVTX

Ikarian Capital's AVTX Position: Q3 2026 in Review

Ikarian Capital held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 90,183 shares worth $1.38M. The position accounts for 0.14% of the portfolio, ranked #116.

Ikarian Capital first reported a position in AVTX in Q4 2019 and has held it in 20 quarters since. The position peaked at $9.22M in Q3 2024. 143 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Ikarian Capital held 90,183 shares of Avalo Therapeutics worth $1.38M as of Q3 2026.
  • Ikarian Capital left its Avalo Therapeutics share count unchanged in Q3 2026.
  • Avalo Therapeutics made up 0.14% of Ikarian Capital's portfolio in Q3 2026, its #116 holding.
  • Ikarian Capital first reported a position in Avalo Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • Ikarian Capital's Avalo Therapeutics position peaked at $9.22M in Q3 2024.
  • 143 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.